Amgen Inc. Stock News

The Pharmaceutical segment offers human health pharmaceutical products in: Oncology, Hospital acute care Immunology Neuroscience Virology Cardiovascular and diabetes Vaccine products, such as preventi

I express frustration with the constant negativity surrounding the idea that beating the market is impossible for the average investor. I share my personal success in beating the market in 2023, with

Amgen (AMGN) reachead $303.17 at the closing of the latest trading day, reflecting a +0.82% change compared to its last close.

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation.is also a consideration.�

It's a new year and apparently there's a new theme on Wall Street for investors. Many of the Magnificent Seven stocks and their high-flying tech peers are off to a difficult start in 2024.

Amgen Inc (NASDAQ:AMGN, ETR:AMG) stock is poised to move higher in 2024 on a thesis its Phase II drug AMG133 for obesity will report positive data, according to Jefferies analysts.   In an update to

Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

The Dow is an excellent starting place if you are looking for foundational holdings. However, some Dow stocks would be best for investors to avoid right now.

In the latest trading session, Amgen (AMGN) closed at $286.53, marking a +0.93% move from the previous day.

Mizuho's Jared Holz joins 'Fast Money' to talk enthusiasm surrounding obesity drugs and if that can endure into 2024.

Per the FDA, Amgen (AMGN) will need to complete an additional confirmatory study on Lumakras in certain lung cancer patients before February 2028 to secure full approval.

Amgen Inc. AMGN said Tuesday that the regulatory review of its supplemental new drug application seeking full approval of Lumakras resulted in a “complete response letter” from the U.S. Food and D

Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.

5 Biotech Acquisition Targets To Accumulate In 2024

Investors in search of high-risk, high-reward investments can often find them among the top biotech stocks to buy. Identifying worthwhile opportunities can be easier said than done when investing in b